Transmedics Group Inc’s filing revealed that its President & CEO Hassanein Waleed H acquired Company’s shares for reported $1.0 million on Aug 06 ’25. In the deal valued at $118.68 per share,8,400 shares were bought. As a result of this transaction, Hassanein Waleed H now holds 477,759 shares worth roughly $56.92 million.
Then, Hassanein Waleed H bought 8,475 shares, generating $985,209 in total proceeds. Upon buying the shares at $116.25, the President & CEO now owns 486,234 shares.
Before that, Basile Edward M sold 4,143 shares. Transmedics Group Inc shares valued at $519,988 were divested by the Director at a price of $125.51 per share. As a result of the transaction, Basile Edward M now holds 2,866 shares, worth roughly $0.34 million.
Evercore ISI initiated its Transmedics Group Inc [TMDX] rating to an Outperform in a research note published on September 16, 2025; the price target was $155. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in early September with a ‘”a Hold”‘ rating. JP Morgan also remained covering TMDX and has decreased its forecast on December 17, 2024 with a “Neutral” recommendation from previously “an Overweight” rating. Needham revised its rating on November 22, 2024. It rated TMDX as “a Hold” which previously was an “a Buy”.
Price Performance Review of TMDX
On Tuesday, Transmedics Group Inc [NASDAQ:TMDX] saw its stock jump 4.25% to $119.15. Over the last five days, the stock has gained 10.04%. Transmedics Group Inc shares have fallen nearly -20.11% since the year began. Nevertheless, the stocks have risen 91.10% over the past one year.
How much short interest is there in Transmedics Group Inc?
A steep rise in short interest was recorded in Transmedics Group Inc stocks on 2025-08-29, growing by 0.6 million shares to a total of 8.27 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 7.67 million shares. There was a rise of 7.25%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 29, 2024 when Oppenheimer resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $125.
